Dr. Kim’s research lies at the interface between chemistry and biology. Specifically, the Kim lab focuses on the development and biological/pharmacological characterization of small molecule inhibitors targeting the proteasome-ubiquitin pathway.
Current research focuses on the development of immunoproteasome inhibitors that can be used as lead compounds in drug development process as well as molecule probes to investigate the function of the immunoproteasome..
Lee H L, Park M H, Song J K, Jung Yuha, Kim Y, Kim Kyung Bo, Hwang D Y, Yoon do Y, Song M J, Han S B, Hong J T. (2016). Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models.Oncotarget, 7(17), 23425-38.
Reichel D, Lee Min-Young, Lee Wooin, Kim Kyung Bo, Bae Younsoo. (2016). Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.Therapeutic delivery, 7(10), 665-681.
Kasam V, Lee N R, Kim Kyung Bo, Zhan C-G. (2014). Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.Bioorganic & Medicinal Chemistry Letters, 24(15), 3614-7.
de Bruin G, Huber E M, Xin B T, van Rooden E J, Al-Ayed K, Kim Kyung Bo, Kisselev A F, Driessen C, van der Stelt M, van der Marel G A, Groll M, Overkleeft H S. (2014). Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.Journal of medicinal chemistry, 57(14), 6197-209.
Park J E, Wu Yadi, Carmony K C, Miller Z, Sharma L K, Lee D M, Kim Doo Young, Lee Wooin, Kim Kyung Bo. (2014). A FRET-based approach for identification of proteasome catalytic subunit composition.Molecular bioSystems, 10(2), 196-200.
Ghosh P, Array Array, Kim Kyung Bo, Stinchcomb Audra L. (2014). Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.Pharmaceutical research, 31(1), 148-59.
Miller Z, Lee Wooin, Kim Kyung Bo. (2014). The immunoproteasome as a therapeutic target for hematological malignancies.Current cancer drug targets, 14(6), 537-48.